(Source: Clavis Pharma ASA) Data presented at the American Society of Hematology annual meeting Oslo, Norway, 10 December 2012 Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed and results were presented* by Dr David Rizzieri from Duke University Medical Center yesterday at the American Society of Haematology annual meeting in Atlanta, GA. Elacytarabine is a novel, patented lipid-conjugated form of the anti-cancer drug...
0 Responses to Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in patients with early stage acute myeloid leukaemia (AML) (Clavis Pharma ASA)